Exxon Mobil Corporation’s (XOM Quick QuoteXOM ) petrochemical joint venture (JV) with Saudi Basic Industries Corporation or SABIC in the U.S. Gulf Coast has commenced commissioning operations. The project is preparing for initial start-up in the fourth quarter, ahead of the earlier schedule.
The new complex near Corpus Christi, TX, incorporates an ethane cracker with 1.8 million metric tons per annum of capacity, which will feed one mono-ethylene glycol and two polyethylene units. The ethane cracker is expected to be the world’s second-largest unit. The mono-ethylene glycol unit will likely be the world’s largest of its kind, with 1.1 million metric tons per annum of capacity. The linear low-density polyethylene facilities will have 650,000 metric tons per annum of capacity each.
The mono-ethylene glycol and two polyethylene units reached mechanical completion by July-end. The project is likely to generate $50 billion of economic benefits in the first six years of operation. It will produce the necessary chemicals utilized in medical, automotive and packaging products.
Top Medical Stocks To Invest In 2023: Ionis Pharmaceuticals, Inc.(IONS)
Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, develops drugs for patients with severe and rare diseases in the United States. The company markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia, and Alicaforsen for ulcerative colitis and pouchitis. Its drugs in Phase III development include Nusinersen for the treatment of patients with spinal muscular atrophy; IONIS-TTRRx for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; Custirsen to treat cancer; and Plazomicin for the treatment of severe bacterial infection. The companys products under development also include IONIS-DMPK-2.5 for myotonic dystrophy type 1; IONIS-HTT for huntington’s disease; ATL1103 for acromegaly; IONIS-SOD1 for amyotrophic lateral sclerosis; IONIS-FXI (BAY 2306001) for clotting disorders; IONIS-APO(a)-L for high Lp; IONIS-ANGPTL3-L for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5 (AZD9150) for cancer; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; RG-101 for hepatitis C virus infection; IONIS-GCGR and IONIS-PTP1B for type 2 diabetes; and IONIS-FGFR4 for obesity. In addition, it is developing IONIS-GCCR for cushing’s syndrome; IONIS-PKK for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5 (AZD5312) for prostate cancer; IONIS-GSK4-L for ocular disease; IONIS-HBV and IONIS-HBV-L for hepatitis B virus infection; and IONIS-DGAT2 for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
- [By ]
LightPath Technologies, Inc. (NASDAQ:LPTH) – Stock analysts at B. Riley issued their Q2 2022 earnings per share (EPS) estimates for shares of LightPath Technologies in a research report issued to clients and investors on Friday, September 10th. B. Riley analyst D. Kang forecasts that the technology company will post earnings per share of ($0.01) for the quarter. B. Riley has a “Buy” rating and a $3.10 price objective on the stock. B. Riley also issued estimates for LightPath Technologies’ Q3 2022 earnings at $0.00 EPS and FY2022 earnings at ($0.01) EPS.
- [By Joseph Griffin]
Headlines about LightPath Technologies (NASDAQ:LPTH) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LightPath Technologies earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 46.9867601112654 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Top Medical Stocks To Invest In 2023: John Hancock Financial Opportunities Fund(BTO)
John Hancock Bank and Thrift Opportunity Fund (the Fund) is a diversified closed-end management investment company. The Fund’s investment objective is long-term capital appreciation. The Fund invests at least 80% of its net assets in equity securities of United States regional banks and lending companies, including commercial and industrial banks, savings and loan associations and bank holding companies, which own or receive a substantial portion of their income from regional banks or thrifts. It may invest in investment-grade debt securities, as well as debt securities rated BB or below by Standard & Poor’s Ratings group (Standard & Poor’s) or Ba or below by Moody’s Investors Service, Inc. (Moody’s), or if unrated by such rating organizations, determined by the Fund’s investment advisor to be of comparable quality.
The Fund’s portfolio includes capital preferred securities, common stocks and short-term investments. It invests in banks and lending companies, including regional banks, diversified banks, other diversified financial services, thrifts and mortgage finance, asset management and custody banks, and consumer finance companies. John Hancock Bank and Thrift Opportunity Fund’s investment advisor is John Hancock Advisers, LLC, a wholly owned subsidiary of John Hancock Financial Services, Inc. The Fund’s sub-advisor is MFC Global Investment Management (U.S.), LLC.
- [By Max Byerly]
Zacks Investment Research upgraded shares of B2Gold (NYSEAMERICAN:BTG) (TSE:BTO) from a hold rating to a buy rating in a report issued on Monday morning. They currently have $3.50 price objective on the basic materials company’s stock.
- [By Max Byerly]
Bottos (CURRENCY:BTO) traded 2.5% lower against the dollar during the one day period ending at 18:00 PM E.T. on October 5th. During the last week, Bottos has traded 10.8% higher against the dollar. One Bottos token can now be bought for $0.0432 or 0.00000652 BTC on cryptocurrency exchanges including Bit-Z, LBank, Bibox and CoinEgg. Bottos has a total market capitalization of $22.04 million and $683,829.00 worth of Bottos was traded on exchanges in the last day.
- [By Stephan Byrd]
B2Gold (TSE:BTO) (NYSE:BTG) had its price objective trimmed by Pi Financial from C$5.25 to C$5.10 in a research report released on Friday.
A number of other research firms have also recently weighed in on BTO. Canaccord Genuity lowered their target price on shares of B2Gold from C$7.00 to C$6.50 in a research note on Tuesday, July 24th. National Bank Financial lowered their target price on shares of B2Gold from C$7.00 to C$6.50 and set an outperform rating on the stock in a research note on Saturday, July 14th. Scotiabank reissued an outperform rating and issued a C$5.00 target price on shares of B2Gold in a research note on Monday, May 28th. Finally, Royal Bank of Canada lowered their target price on shares of B2Gold from C$5.00 to C$4.50 and set an outperform rating on the stock in a research note on Tuesday, May 22nd. Six investment analysts have rated the stock with a buy rating, B2Gold presently has a consensus rating of Buy and an average target price of C$5.38.